Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Iversen

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Neurochemistry International|March 10, 2007
The metabolic role of isoleucine in detoxification of ammonia in cultured mouse neurons and astrocytesMaja L Johansen, Lasse K Bak, Arne Schousboe, et al.
BJU International|March 19, 2013
Survival after radical prostatectomy for clinically localised prostate cancer: a population-based studyMartin Andreas Røder, Klaus Brasso, Ib Jarle Christensen, et al.
Clinical Genitourinary Cancer|October 10, 2017
Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United StatesMathias Dyrberg Loft, Kasper Drimer Berg, Andreas Kjaer, et al.
The Journal of Urology|November 16, 2004
Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6Peter Iversen, Jan-Erik Johansson, Pär Lodding, et al.
European Urology Oncology|July 6, 2019
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical TrialAndrew J Armstrong, Ping Lin, Celestia S Higano, et al.
European Heart Journal. Cardiovascular Imaging|March 20, 2019
Quantitative estimation of extravascular lung water volume and preload by dynamic 15O-water positron emission tomographyRoni Ranghøj Nielsen, Jens Sörensen, Lars Tolbod, et al.
Urology|July 4, 2012
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patientsJan-Erik Damber, Teuvo L J Tammela, Peter Iversen, et al.
The Journal of Urology|May 7, 2018
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with AntiandrogensE David Crawford, Paul F Schellhammer, David G McLeod, et al.
Scandinavian Journal of Urology and Nephrology|April 25, 2008
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5Per Olov Hedlund, Jan-Erik Damber, Inger Hagerman, et al.
Oncology and Therapy|June 16, 2025
Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety StudyRachel Weinrib, Joan Fortuny, David Martinez, et al.
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Neurochemistry International|March 10, 2007
The metabolic role of isoleucine in detoxification of ammonia in cultured mouse neurons and astrocytesMaja L Johansen, Lasse K Bak, Arne Schousboe, et al.
BJU International|March 19, 2013
Survival after radical prostatectomy for clinically localised prostate cancer: a population-based studyMartin Andreas Røder, Klaus Brasso, Ib Jarle Christensen, et al.
Clinical Genitourinary Cancer|October 10, 2017
Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United StatesMathias Dyrberg Loft, Kasper Drimer Berg, Andreas Kjaer, et al.
The Journal of Urology|November 16, 2004
Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6Peter Iversen, Jan-Erik Johansson, Pär Lodding, et al.
European Urology Oncology|July 6, 2019
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical TrialAndrew J Armstrong, Ping Lin, Celestia S Higano, et al.
European Heart Journal. Cardiovascular Imaging|March 20, 2019
Quantitative estimation of extravascular lung water volume and preload by dynamic 15O-water positron emission tomographyRoni Ranghøj Nielsen, Jens Sörensen, Lars Tolbod, et al.
Urology|July 4, 2012
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patientsJan-Erik Damber, Teuvo L J Tammela, Peter Iversen, et al.
The Journal of Urology|May 7, 2018
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with AntiandrogensE David Crawford, Paul F Schellhammer, David G McLeod, et al.
Scandinavian Journal of Urology and Nephrology|April 25, 2008
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5Per Olov Hedlund, Jan-Erik Damber, Inger Hagerman, et al.
Oncology and Therapy|June 16, 2025
Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety StudyRachel Weinrib, Joan Fortuny, David Martinez, et al.
Pageof 16